Crossref

1. A Phase I Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety Profile of a Sublingually Administered Cannabidiol /Delta 9-tetrahydrocannabidiol (10: 1) Regimen in Diabetes Type 2 Patients

- Shima Afshar

- Shayesteh Khalili

- Gholamreza Amin

- Mohammad Abbasinazari